Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Free Cash Flow: 2014-2024

Historic Free Cash Flow for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to -$128.7 million.

  • Axsome Therapeutics' Free Cash Flow rose 105.28% to $988,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.4 million, marking a year-over-year increase of 23.66%. This contributed to the annual value of -$128.7 million for FY2024, which is 11.66% up from last year.
  • As of FY2024, Axsome Therapeutics' Free Cash Flow stood at -$128.7 million, which was up 11.66% from -$145.7 million recorded in FY2023.
  • Axsome Therapeutics' Free Cash Flow's 5-year high stood at -$78.5 million during FY2020, with a 5-year trough of -$145.7 million in FY2023.
  • Its 3-year average for Free Cash Flow is -$130.5 million, with a median of -$128.7 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 69.22% in 2020, then rose by 11.66% in 2024.
  • Axsome Therapeutics' Free Cash Flow (Yearly) stood at -$78.5 million in 2020, then crashed by 38.26% to -$108.5 million in 2021, then fell by 8.00% to -$117.2 million in 2022, then decreased by 24.27% to -$145.7 million in 2023, then grew by 11.66% to -$128.7 million in 2024.